The devastating impact of COVID-19 on global health shows the need to increase our
pandemic preparedness. Recombinant therapeutic antibodies were successfully used to …

The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants
has sparked concern over the continued effectiveness of existing therapeutic antibodies and …

Bispecific antibodies have emerged as a promising strategy for curtailing severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

The emergence and rapid spread of the B. 1.1. 7 lineage (VOC-202012/01) SARS-CoV-2
variant has aroused global concern. The N501Y substitution is the only mutation in the …

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …

Monoclonal antibodies are an efficacious therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape …

The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …

Introduction The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants has caused unprecedented health and socioeconomic crises, necessitating …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages
that are more transmissible and resistant to currently approved antibody therapies poses a …